trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol (2013) 14(6):461–71. doi:...
1、Guven DC, Kaya MB, Fedai B, et al. HER2-low breast cancer could be associated with an increased risk of brain metastasis. Int J Clin Oncol. 2022 Feb;27(2):332-339. 2、Junji Tsurutani, et al. Subgroup Analysis of Patients ...
[3] SESS-729 Pyrotinib or placebo in combination with trastuzumab and docetaxel for untreated HER2-positive metastatic breast cancer (mBC): prespecified final analysis of progression-free survival (PFS) of the phase 3 PHILA trial. [4] RF3-04 NRG-BR004: A Randomized, Double-Blind, Phase III...
[22] Grinda T, et al. Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort. ESMO Open. 2021 Jun;6(3):100114. [23] Swain SM, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive met...
[11]Curigliano G, Castelo-Branco L, Gennari A, et al. ESMO Metastatic Breast Cancer Living Guidelines, v1.1 May 2023. [12]Jin J, Li B, Cao J, et al. Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer. J Transl Med. 2023 Jun 1;21(1...
3. Modi S, Jacot W, Iwata H, et al. 376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study[J]....
[14] Cortés J, Hurvitz SA, Im SA, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nat Med. Published online June 2, 2024. doi:10.1038/s41591-024-03021-7. ...
Bonotto M, Gerratana L, Iacono D, et al. Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines? Oncologist. 2015;20(7):719-724. ...
[9]Giuliano AE, Ballman KV, et al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.JAMA. 2017 Sep 12;318(10):918-926. ...
[13]Mendes D, Alves C, Afonso N, Cardoso F, Passos-Coelho JL, Costa L, Andrade S, Batel-Marques F. The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer--a systematic review. Breast Cancer Res. 2015;17:140. ...